Merck Sharp + Dohme Corp.

Schering Corporation

Opko Health, Inc.

Merck Sharp & Dohme LLC

Schering-plough Corporation

Msd Italia S.r.l.

Scherig Corporation

Dong Xiao

Anandan Palani

Neng-Yang Shih

Xianhai Huang

Sunil Paliwal

Cheng Wang

Robert G Aslanian

Shuwen He

Ravi P Nargund

Peng Li

Xing Dai

Michael W Miller

Amjad Ali

Barbara A Pio

Casey Cameron McComas

Ying Huang

Younong Yu

Pauline C Ting

Christopher W Boyce

Hong Liu

Brian Alexander McKittrick

Qun Dang

Kevin D McCormick

Michael Berlin

Hongjun Zhang

Duane E DeMong

Andrew William Stamford

Nigel J Liverton

Tesfaye Biftu

Michael Man-Chu Lo

John J Piwinski

David J Blythin

Phieng Siliphaivanh

Joey Lee Methot

Ho-Jane Shue

William K Hagmann

Hao Wu

Duane A Burnett

Yongxin Han

Alexander Pasternak

Sung-Sau So

Hubert B Josien

Stephane L Bogen

Tao Guo

Elizabeth M Smith

Joseph Michael Kelly

Steven L Colletti

Michael T Rudd

Liangqin Guo

Guoqing Li

Cheng Zhu

Hon-Chung Tsui

Michelle Laci Wrobleski

Gregory A Reichard

Ashwin Umesh Rao

Xiao Chen

Nicolas Zorn

Xuanjia Peng

Yan Guo

Christopher W Plummer

Purakkattle J Biju

Robert D Mazzola, Jr

Tin-Yau Chan

Lin Chu

Richard Soll

Harry R Chobanian

Rongze Kuang

Yeon-Hee Lim

Junying Zheng

Linda Brockunier

Wei Zhou

Heping Wu

Walter Won

Helen Y Chen

Timothy J Henderson

Qiaolin Deng

Tao Yu

Clare London

Paul Tempest

Jayaram R Tagat

Qin Jiang

Haiqun Tang

Dexi Yang

Jing Su

Li Xiao

Rajan Anand

John P Caldwell

Manuel De Lera Ruiz

De-Yi Yang

Frank Narjes

Uwe Koch

Tanweer A Khan

Dane James Clausen

Petr Vachal

Qinglin Pu

Yonglian Zhang

Joel M Harris

Anthony Donofrio

Joerg Habermann

Anilkumar G Nair

The present invention is directed to cyclopentapyrrole, furopyrrole and azabicycloheptane compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Cyclopentapyrrole orexin receptor agonists

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

Factor XI activation inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic bicyclic compounds

Antidiabetic spirochroman compounds

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: 'Z', Rand Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Aminopyrazine compounds with A2A antagonist properties

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. 

[object Object]

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic compounds

Disclosed are compounds of Formula G1: where 'R'. 'R' to &#x201c;R&#x201d;, &#x201c;n&#x201d;, &#x201c;m&#x201d;, &#x201c;p&#x201d;, &#x201c;W&#x201d;, &#x201c;X&#x201d;, &#x201c;Y&#x201d;, and &#x201c;Z&#x201d; are defined herein, which compounds are antagonists of Areceptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which Areceptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties

A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NKreceptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

A NKantagonist having the formula (I), wherein Arand Arare optionally substituted phenyl or heteroaryl, Xis an ether, thio or imino linkage, Rand Rare not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.

Disclosed are compounds of Formula A: (structurally represented) where 'RG1', 'RG2a', &#x201c;RG4&#x201d;, &#x201c;RG5&#x201d;, &#x201c;MG1&#x201d;, &#x201c;n&#x201d; and &#x201c;m&#x201d; are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. 

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I) 

Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C

Growing community of inventors

Warren, NJ, United States of America

Dong Xiao